Genome editing-based therapies become the predominant technology of the 21st century with promising statements about genetic diseases treatments. Genome editing tools recently emerged but they suffer from an absence of standardization and their applications remain limited.
In this context, Quidditas developed a novel genome editing platform which permits an absolute genetic recombination.
Compatible with a larger scope of applications, from bioprocess improvement to genetic disorders treatment, this revolutionary technique will have a major impact in the synthetic Bio field.
So “Let’s cure from the beginning!”
Company Details
- Employees
- 4
- Founded
- -
- Address
- Liège, Be
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Genome Editing.
- HQ
- liège
Quidditas Questions
Quidditas's website is https://www.quidditastherapeutics.com/
Quidditas's LinkedIn profile is https://be.linkedin.com/company/quidditas
Quidditas has
4 employees.
View email and phone details for 4
employees at Quidditas.
Quidditas's industry is
Biotechnology Research
Quidditas's top competitors are
Azalea Vision,
Edelris,
Remynd,
Gynaia,
Signatur Biosciences,
Aboleris Pharma,
Quantoom Biosciences,
Epics Therapeutics,
Rejuvenate Biomed,
Ispiron Biotechnologies.
Quidditas's categories are Biotechnology Research
Quidditas's founding year is 2022
